


IN THE CLAIMS

The following listing of claims will replace all prior versions and listings of claims in the present application.

1–9. (Canceled)

10. (Previously presented) A pharmaceutical composition comprising (S)-2-N-propylamino-5-hydroxytetralin or a pharmaceutically acceptable salt or prodrug thereof, and at least one pharmaceutically acceptable carrier or adjuvant, wherein the prodrug is of the formula




or a salt thereof;

wherein R¹ is selected from the group consisting of acyl, alkoxy carbonyl, cycloalkoxy carbonyl, aryloxy carbonyl, acetal, ketal, -C(O)NR²R³, -C(O)NHR², -P(O₂H)OR² and -P(O₂H)R², wherein R² and R³ are independently selected from H, C_{1–6} alkyl, C_{3–10} cycloalkyl, benzyl and phenyl and

wherein the at least one pharmaceutically acceptable carrier or adjuvant is selected from the group consisting of fillers, disintegrants, binders, lubricants, stabilizers, flavors, antioxidants, preservatives, dispersants, buffers and electrolytes.

11. (Previously presented) The composition of Claim 10, comprising (S)-2-N-propylamino-5-hydroxytetralin or a pharmaceutically acceptable salt thereof.
12. (Previously presented) The composition of Claim 10, comprising a prodrug or a salt thereof wherein R¹ is selected from C_{1–6} alkylcarbonyl, C_{3–10} cycloalkylcarbonyl, benzoyl, -C(O)NR²R³ and -C(O)NHR².
13. (Previously presented) The composition of Claim 10, that is adapted for transdermal, transmucosal or parenteral administration.

14. (Previously presented) The composition of Claim 10, wherein the (S)-2-N-propylamino-5-hydroxytetralin or salt or prodrug thereof is present as a pure (S)-enantiomer.
15. (Withdrawn) A method for treatment or prophylaxis of a disease or for ablation in a subject, comprising administering to the subject (S)-2-N-propylamino-5-hydroxytetralin or a pharmaceutically acceptable salt or prodrug thereof, wherein the prodrug is of the general formula



wherein R¹ is selected from the group consisting of acyl, alkoxy carbonyl, cycloalkoxy carbonyl, aryloxy carbonyl, acetal, ketal, -C(O)NR²R³, -C(O)NHR²,


-P(O₂H)OR² and -P(O₂H)R², wherein R² and R³ are independently selected from H, C₁₋₆ alkyl, C₃₋₁₀ cycloalkyl, benzyl and phenyl, or a salt thereof; and

wherein the disease is selected from the group consisting of depressions, anxiety disorders, sexual dysfunctions, galactorrhea, acromegaly, glaucoma, cognitive disorders, restless leg syndrome, attention deficit hyperactivity syndrome (ADHS), hyperprolactinemia, hyperprolactinoma, eating disorders, dopa-sensitive dyskinesias, Parkinson-associated movement disorders, dopa- and neuroleptic-induced movement disorders, cocaine, alcohol, opiate and nicotine addictions, and neurodegenerative disorders.

16. (Withdrawn) The method of Claim 15, wherein the disease is selected from the group consisting of restless leg syndrome, L-dopa-sensitive dyskinesias, Parkinson-associated movement disorders, L-dopa- and neuroleptic-induced movement disorders, and cocaine, alcohol, opiate and nicotine addictions.
17. (Withdrawn) The method of Claim 15, wherein the disease is a movement disorder which is
 - (a) morbus Parkinson associated,


- (b) induced by L-dopa, or
- (c) induced by a neuroleptic.

18. (Withdrawn) A method for treating a disease that responds to therapy by dopamine or dopamine agonists, comprising administering to a subject having the disease (S)-2-N-propylamino-5-hydroxytetralin or a pharmaceutically acceptable salt or prodrug thereof, wherein the prodrug is of the general formula



wherein R¹ is selected from the group consisting of acyl, alkoxycarbonyl, cycloalkoxycarbonyl, aryloxycarbonyl, acetal, ketal, -C(O)NR²R³, -C(O)NHR², -P(O₂H)OR² and -P(O₂H)R², wherein R² and R³ are independently selected from H, C₁₋₆ alkyl, C₃₋₁₀ cycloalkyl, benzyl and phenyl, or a salt thereof.

19. (Currently amended) A compound having the formula



or a salt thereof;

wherein R¹ is selected from the group consisting of acyl, alkoxycarbonyl, cycloalkoxycarbonyl, aryloxycarbonyl, acetal, ketal, -C(O)NR²R³, -C(O)NHR², -P(O₂H)OR² and -P(O₂H)R², wherein R² and R³ are independently selected from H, C₁₋₆ alkyl, C₃₋₁₀ cycloalkyl, benzyl and phenyl;

said compound being in the (S)-configuration; and

wherein said compound, when administered to a human body, is cleaved, processed or metabolized to (S)-2-N-propylamino-5-hydroxytetralin.

Serial No. 10/587,637

6102-000034/US/NP

RCE, Amendment G and response to office action dated April 1, 2009

June 29, 2009

20. (Previously presented) The compound of Claim 19, wherein R¹ is selected from C₁₋₆ alkylcarbonyl, C₃₋₁₀ cycloalkylcarbonyl, benzoyl, –C(O)NR²R³ and –C(O)NHR².
21. (Canceled)